The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000741381
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
1/06/2026
Date registered
Help: Date registered
19/06/2026
Date last updated
Help: Date last updated
19/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
19/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Allopurinol deprescribing in people with gout on haemodialysis: a pilot study
Scientific title
“Safety, efficacy, and feasibility of allopurinol deprescribing in people with gout on haemodialysis: a pilot study”
Additional trial identifiers [1] 317437 0
None
Universal Trial Number (UTN)
Trial acronym
DEPUR-HD
Related trial records

Health condition
Health condition(s) studied:
Gout 342126 0
Haemodialysis 342316 0
Chronic kidney disease 342317 0
Condition category
Condition code
Musculoskeletal 338239 338239 0 0
Other muscular and skeletal disorders
Renal and Urogenital 338443 338443 0 0
Kidney disease

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
In consenting participants, allopurinol doses will be gradually reduced in a stepwise manner by 50 mg per month until complete discontinuation. Serum urate concentrations will be measured pre-dialysis at baseline and two weeks after each dose reduction. Following discontinuation, participants will be monitored monthly for six months. Deprescribing of allopurinol will occur over 2-7 months (depending on the initial dose), followed by a 6-month follow up period. The overall duration of the intervention period is between 8 and 15 months.
Gout flares will be assessed using validated Gaffo’s criteria, defined by the presence of three or more of the following: patient-defined flare, pain at rest greater than 3 on a 0–10 scale, at least one swollen joint, and at least one warm joint.
To minimise the risk of gout flares during deprescribing, participants will receive prophylaxis as determined by the treating nephrologist. This may include colchicine 250 micrograms twice weekly, or a short course of prednisolone 12.5–25 mg for 3 days at each dose reduction. Participants receiving colchicine will undergo monitoring for gastrointestinal adverse effects and periodic full blood count testing. If a gout flare or significant adverse event occurs, deprescribing will be paused and participation will cease. Allopurinol may be re-initiated at the discretion of the treating clinician in accordance with standard care.
All study procedures will be embedded within routine haemodialysis care, with blood sampling incorporated into standard pre-dialysis testing to minimise participant burden.
Intervention code [1] 334231 0
Treatment: Drugs
Description of the comparator or control
No control group. This is a single-arm, uncontrolled pilot interventional study.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345611 0
Safety of allopurinol deprescribing
Timepoint [1] 345611 0
Participants will assess fortnightly during the during allopurinol deprescribing period (over 2-7 months) and monthly during the six-month post-discontinuation follow-up period
Primary outcome [2] 345612 0
Efficacy of allopurinol deprescribing
Timepoint [2] 345612 0
Efficacy will be determined at the final study visit (up to 15 months since commencing deprescribing).
Secondary outcome [1] 462392 0
Feasibility of allopurinol deprescribing: Recruitment rate
Timepoint [1] 462392 0
Assessed continuously throughout the study period, up to 15 months (fortnightly during the during allopurinol deprescribing period (over 2-7 months) and monthly during the six-month post-discontinuation follow-up period)
Secondary outcome [2] 463108 0
Feasibility of allopurinol deprescribing: Retention rate
Timepoint [2] 463108 0
Retention rate will be calculated at the final study visit (up to 15 months since commencing deprescribing)

Eligibility
Key inclusion criteria
Adult patients with end-stage CKD and controlled chronic gouty arthritis, currently prescribed allopurinol, receiving haemodialysis for at least 4 weeks will be potentially eligible. Chronic gouty arthritis is defined by the Gout, Hyperuricemia and Crystal-Associated Disease Network as persistent joint inflammation induced by monosodium urate crystals. Controlled gout will be defined as maximum of one gout flare in last 6 months. Pre-dialysis serum urate concentrations will be measured for potentially eligible participants and only participants with serum urate less than or equal to 0.36 mmol/L will be included.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Presence of gouty tophi, planned kidney transplant, or conversion to peritoneal dialysis within one year. Patients unable to give consent will also be excluded. Tophi would be identified using physical measurement techniques as required by the framework of the Outcomes Measures in Rheumatology (OMERACT)

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
This is a pilot feasibility study and is not powered for hypothesis testing. A target sample size of 25 participants was selected based on feasibility considerations and local patient availability.
Descriptive statistics will be used to summarise safety, efficacy, and feasibility outcomes.
The proportion of participants successfully discontinuing allopurinol will be reported. Associations between stage of dose reduction and occurrence of gout flares will be explored using appropriate statistical tests (t-test or Mann–Whitney U test depending on distribution).
Categorical outcomes will be analysed using chi-square tests.
Analyses will follow the intention-to-treat principle

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 322013 0
University
Name [1] 322013 0
The University of Sydney
Country [1] 322013 0
Australia
Primary sponsor type
University
Name
The University of Sydney
Address
Country
Australia
Secondary sponsor category [1] 324890 0
None
Name [1] 324890 0
Address [1] 324890 0
Country [1] 324890 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320545 0
Western Sydney Local Health District Human Research Ethics Committee
Ethics committee address [1] 320545 0
Ethics committee country [1] 320545 0
Australia
Date submitted for ethics approval [1] 320545 0
Approval date [1] 320545 0
02/03/2026
Ethics approval number [1] 320545 0
2025/ETH02178

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150822 0
A/Prof Sophie Stocker
Address 150822 0
Rm No N405, Building No A15, The University of Sydney, Camperdown, NSW 2006
Country 150822 0
Australia
Phone 150822 0
+61 2 9114 4756
Fax 150822 0
Email 150822 0
Contact person for public queries
Name 150823 0
Sophie Stocker
Address 150823 0
Rm No N405, Building No A15, The University of Sydney, Camperdown, NSW 2006
Country 150823 0
Australia
Phone 150823 0
+61 2 9114 4756
Fax 150823 0
Email 150823 0
Contact person for scientific queries
Name 150824 0
Sophie Stocker
Address 150824 0
Rm No N405, Building No A15, The University of Sydney, Camperdown, NSW 2006
Country 150824 0
Australia
Phone 150824 0
+61 2 9114 4756
Fax 150824 0
Email 150824 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: IPD data will not be made available in accordance with our ethics approval.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.